现实世界治疗模式和基因测试在欧洲的一个转移性割抵抗性前列腺癌的设置
Elena Castro1, Chinelo Orji2, Amanda Ribbands3
1Medical Oncology, Hospital Universitario 12 de Octubre, Madrid, Spain.
Future oncology (London, England)
|March 19, 2025
概括
现实数据显示,虽然雄激素受体通路抑制剂在转移性割抵抗性前列腺癌 (mCRPC) 中的使用正在增加,但同源重组修复突变 (HRRm) 测试仍然很低,可能会推迟向治疗.
科学领域:
- 在瘤学瘤学.
- 泌尿器科 泌尿器科 泌尿器科 泌尿器科
- 临床药房 临床药房
背景情况:
- 转移性割抵抗性前列腺癌 (mCRPC) 提出了复杂的治疗挑战.
- 了解现实世界的治疗模式和诊断测试对于优化患者护理至关重要.
研究的目的:
- 描述治疗模式,选择治疗的原因,以及在欧洲mCRPC群体中对同源重组修复突变 (HRRm) 的测试.
- 确定HRRm测试中的潜在漏洞,这些漏洞可能会影响获得向治疗的机会.
主要方法:
- 在五个欧洲国家 (法国,德国,意大利,西班牙,英国) 的医生和患者进行了横截面调查.
- 对1,737名mCRPC患者的临床特征,一线和后续治疗以及HRRm测试收集的数据.
- 主要使用描述性分析,使用费舍尔的精确测试来比较治疗原因.
主要成果:
- 大多数患者 (73%) 在一线mCRPC中是先前接受过雄激素受体通路抑制剂 (ARPi) 的患者,其中60%接受了ARPi,24%接受化疗.
- 在先前接受ARPi治疗的患者中,60%接受化疗,21%接受mCRPC的ARPi.
- 总体HRRm测试率为37%,在不同国家,专业和实践环境中观察到差异.
结论:
- 在mCRPC中的现实世界治疗模式通常与临床指南保持一致.
- 在mCRPC之前观察到ARPi的使用增加.
- 低HRRm测试率表明mCRPC患者可能无法及时获得潜在更有效的向治疗.
更多相关视频
07:25A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
Published on: March 6, 2018
12.9K
12:13Sequencing Small Non-coding RNA from Formalin-fixed Tissues and Serum-derived Exosomes from Castration-resistant Prostate Cancer Patients
Published on: November 19, 2019
6.7K
相关概念视频
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...